Company: ACBM
Filing Date: 2025-07-23
Form Type: 10-Q
Source: 0001640334-25-001281
Chunk: 4

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-23
Form: 10-Q
Item: Item 1
Chunk 4
---
Net loss  -   -   -   -   -   -   (1,589,490)  (1,589,490)                                 Balance, September 30, 2023  -  $-   60,042,000  $60,042  $32,297,603  $-  $(32,597,258) $(239,613)

The accompanying notes are an integral part of these unaudited financial statements.

 6Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Cash Flows

(Unaudited) 

   Nine Months Ended     September 30,    2024  2023        CASH FLOWS FROM OPERATING ACTIVITIES      Net loss $(31,624) $(8,789,333)Adjustments to reconcile net loss to net cash used in operating activities:        Imputed interest - related parties  3,134   2,367 Amortization of deferred stock compensation   -   8,060,983 Provision for doubtful accounts  -   480,000 Provision for purchase deposit write off  -   12,000 Changes in operating assets and liabilities:        Accounts receivable  -   158,500 Prepaid expenses  1,250   (3,815)Accounts payable and accrued expenses  1,063   76,465 Net cash used in operating activities  (26,177)  (2,833)         CASH FLOWS FROM FINANCING ACTIVITIES        Advances from related parties  26,502   252 Net cash provided by financing activities  26,502   252          Net change in cash  325   (2,581)Cash at beginning of period  376   5,852 Cash at end of period $701  $3,271          SUPPLEMENTAL CASH FLOW INFORMATION:        Cash paid for income taxes $-  $- Cash paid for interest $-  $- 

The accompanying notes are an integral part of these unaudited financial statements.

 7Table of Contents

ACRO BIOMEDICAL CO., LTD.

Notes to Financial Statements